“Staying safe” – a narrative review of falls prevention in people with Parkinson’s – “PDSAFE”
EditorParkinson’s disease demonstrates a spectrum of motor and non-motor symptoms. Falling is common and disabling.
Science
3 hot topics from the world’s largest dementia research conference
Aoife Kiely, Research Communications Officer, shares her highlights from the AAIC with insights from Dr Doug Brown, Chief Policy and Research Officer.
Across Time and Space: Machine Learning Reveals Paths to Dementia
Developing computational algorithms & machine-learning techniques, to transform cross-sectional imaging data to a longitudinal picture and reconstruct the sequence of disease progression.
An introduction to overviews of reviews: planning a relevant research question and objective for an overview
Overviews of systematic reviews are a relatively new approach to synthesising evidence, and research methods and associated guidance are developing.
Analysing the market for care homes for older people using Care Quality Commission and other data
In this webinar Professor Ruth Hancock analyses the market for care homes for older people using Care Quality Commission and other data.
Are Tauopathies Caused by Neuronal and Glial Senescence?
In AD, tau tangles correlate closely with neurodegeneration, but how they work their mischief remains unclear… or does it?
Bad Synergy—Together, Vascular Problems and Aβ Hasten Memory Slippage
People at risk for future cardiovascular events also face greater odds of developing memory problems, according to a May 23 study in JAMA Neurology.
Bump in the Road or Disaster? BACE Inhibitors Worsen Cognition
Merck shook the field with news that people on verubecestat scored worse than those on placebo – find out more in this post from AlzForum
Could repurposing a liver disease drug improve mitochondrial dysfunction in Alzheimer’s?
New study reveals that a drug that used to treat liver diseases could help to restore cells damaged by Alzheimer’s
Cracking the mysteries of Alzheimer’s disease
With Pfizer shutting down its neuroscience unit and a long list of failed late-stage trials, the sheer difficulty of improving the treatment of Alzheimer’s disease has become painfully clear. How can researchers crack the mystery of this much-feared neurodegenerative disease?
CSF tau and the CSF tau/ABeta ratio for the diagnosis of Dementias
This review, aims to assess the ability of CSF tau biomarkers (t-tau and p-tau) and the CSF tau (t-tau or p-tau)/ABeta ratio to enable the detection of Alzheimer’s disease pathology in patients with mild cognitive impairment (MCI).